Old Web
English
Sign In
Acemap
>
Paper
>
Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a
Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a
2016
Tomas Kalincik
J. W. L. Brown
Neil Robertson
Mark Willis
Neil Scolding
Owen R. Pearson
Tjalf Ziemssen
Michael Hutchinson
Christopher McGuigan
Vilija Jokubaitis
Tim Spelman
Dana Horakova
Eva Havrdova
M. Trojano
Guillermo Izquierdo
Alessandra Lugaresi
Alexandre Prat
Marc Girard
Pierre Duquette
Pierre Grammond
Raed Alroughani
Eugenio Pucci
P. Sola
Raymond Hupperts
Jeannette Lechner-Scott
R. Fernández Bolaños
Murat Terzi
Vincent Van Pesch
Csilla Rozsa
F. GrandMaison
C. Boz
Franco Granella
M. Slee
D. Spitaleri
Javier Olascoaga
Roberto Bergamaschi
G. Iuliano
Freek Verheul
Steve Vucic
Pamela A. McCombe
Suzanne J. Hodgkinson
Krisztina Kovács
J.L. Sánchez Menoyo
R. Ampapa
Magdolna Simó
Cristina Ramo
Edgardo Cristiano
Michael Barnett
Helmut Butzkueven
Alasdair Coles
Keywords:
Oncology
Medicine
Pathology
Interferon beta-1a
Alemtuzumab
Fingolimod
Internal medicine
Natalizumab
Physical therapy
treatment outcome
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]